The effects of varespladib, a drug that inhibits the enzyme secretory phospholipase A2 on cardiovascular risk in patients with acute coronary syndrome (ACS; such as heart attack or unstable angina) was determined by Stephen J. Nicholls, M.B.B.S., Ph.D., of the South Australian Health and Medical Research Institute and University of Adelaide, Adelaide, Australia, and colleagues. Despite contemporary therapies, patients with ACS face a substantial risk of early, ...You have just read an article categorized health
titled Risk of Cardiovascular Event Is Not Lowered Upon Use of Enzyme Inhibitors Among Patients With Recent ACS.
Written by:
editor - Thursday, November 28, 2013
There are currently no comments for "Risk of Cardiovascular Event Is Not Lowered Upon Use of Enzyme Inhibitors Among Patients With Recent ACS"
Post a Comment